Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.

Area of Science:

• Neuroimmunology
• Biomarker Discovery

Background:

• Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
• Accurate assessment of MS disease activity is crucial for effective management and treatment monitoring.

Purpose of the Study:

• To investigate the diagnostic and prognostic utility of soluble interleukin-2 receptor (sIL-2R) levels in multiple sclerosis.
• To compare the efficacy of sIL-2R as a biomarker against established clinical and laboratory parameters.

Main Methods:

• Quantification of sIL-2R levels using enzyme-linked immunosorbent assay (ELISA).
• Analysis of serum and cerebrospinal fluid (CSF) samples from patients with active MS, remitting MS, and controls.
• Comparison of sIL-2R levels with CSF IgG ratio, CD4/CD8 ratio, myelin basic protein, and oligoclonal bands.

Main Results:

• Significantly elevated sIL-2R levels were found in the serum and CSF of MS patients during relapse compared to remission and controls.
• CSF sIL-2R demonstrated higher sensitivity and specificity for evaluating MS disease activity than other tested parameters.
• sIL-2R levels correlated with disease activity, particularly in the cerebrospinal fluid.

Conclusions:

• Serum and CSF sIL-2R levels serve as valuable indicators of active disease in multiple sclerosis.
• sIL-2R measurement offers a sensitive and specific method for assessing MS disease activity.
• This biomarker may aid in clinical decision-making and monitoring therapeutic responses in MS patients.